OncologyStat.com reports there is some good news for multiple myeloma patients with chromosomal abnormalities:
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
In this large, retrospective analysis of patients with newly diagnosed multiple myeloma, bortezomib-based induction therapy before high-dose melphalan and stem cell transplantation was associated with improved survival in patients with t(4;14) but not del(17p) cytogenetics when compared with patients who received vincristine, doxorubicin, and dexamethasone induction.
Please note patients with 17p deletions did not see much benefit. This report is a must read for any patient with chromosomal issues. Go to: Vel/Dex Shows Survival Benefit For Some for more.
Feel good and keep smiling! Pat